TrialPloS one2016

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).

Jacques De Grève et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.